Back

Cancer therapy-related cardiovascular toxicity: what is the accuracy of baseline cardiovascular risk stratification in the prediction of its occurrence?

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in Cardiovascular disease in special populations (1) Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nuno Cotrim

District Hospital of Santarem, Santarem (Portugal)

6 More presentations in this session

Presentation thumbnail
Long-term cardiovascular outcomes after severe burn injury
Ms V. Krbcova Moudra (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of 18F-fluorodeoxyglucose positron emission tomography and 67gallium scintigraphy in cardiac sarcoidosis.
Doctor Y. Takigami (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
Impact of cardiovascular disease burden on the severity of COVID-19 patients
Doctor D. De Almeida Fernandes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Routine Ankle-Brachial Index (ABI) measurement: a window into atherosclerosis and early left ventricular dysfunction in patients diagnosed with cancer
Doctor M. Slieman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Morbidity and mortality of cardio-oncology patients: is there any link to baseline cardiovascular risk?
Doctor B. Andrade (Santarem, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in Cardiovascular disease in special populations (1)

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Current challenges in risk stratification of cancer therapy-related cardiovascular toxicity
thumbnail
Congress Presentation
Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab
thumbnail
Congress Presentation
Echocardiographic variables may improve baseline risk prediction of cancer therapy related cardiac dysfunction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources